Q3 2026
Nov 14, 2026
Cellebrite shares fell 9.2% after earnings, despite Q3 results above company guidance. The transcript points to lingering concern about the outlook: management described the U.S. go-to-market response as improved after Q2 and said updated financial guidance would follow, but the supplied remarks do not include the revised outlook.
Key takeaways
- CEO said Q3 ARR, revenue and adjusted EBITDA finished above company guidance; international performance and a reaccelerating U.S. federal business drove top-line growth.
- EMEA grew 22% and Asia-Pacific 31%. Two large U.S. federal customers each increased spending by more than 20% year over year.
- Genesis ended its first full quarter with $2 million in ARR. Inseyets conversions rose from nearly 65% of the install base at Q2-end to 75% at Q3-end.
- Advanced unlocks doubled customers versus Q2, with strong sequential ARR growth; defense and intelligence continued growing in the mid-20s.
- Management said it plans to introduce an on-premise AI version of Genesis before year-end and expects to deliver updated mobile-forensics capabilities and next-generation hardware before year-end.
Q2 2026
Aug 16, 2026
Cellebrite's shares fell 27% after management acknowledged a significant deceleration in deal closings, primarily due to delayed large transactions and weaker-than-expected ARR uplift from their Insights solution, prompting a cut to full-year ARR and revenue guidance.
Key takeaways
- The anticipated Q2 acceleration in Annual Recurring Revenue (ARR) and revenue did not materialize, largely due to delays in closing several large U.S. federal and European government contracts.
- Additional administrative and procurement hurdles tied to Cellebrite’s foreign entity status impacted timing on major deals.
- The Insights digital forensic product, while adopted by nearly 65% of the installed base, delivered lower ARR uplift than expected, especially in the U.S. state and local government segment.
- Management cited increased complexity in cloud and AI-related deals, involving longer procurement cycles and more stakeholders.
- Reflecting these challenges and delayed product launches, Cellebrite revised downward its full-year ARR and revenue outlook.
Q1 2026
May 16, 2026
Cellebrite's stock gained 7.3% post-earnings, driven by ARR growth that met or exceeded guidance and the promising early adoption of its new AI product, Genesis, signaling potential upside beyond current revenue expectations.
Key takeaways
- Annual Recurring Revenue (ARR) grew 21% year-over-year to $493 million, meeting or surpassing the high end of guidance.
- Adjusted EBITDA increased 29% year-over-year to $30.6 million.
- Free cash flow margin for the trailing 12 months remained strong at 32%.
- Genesis, the newly launched AI-enabled investigative analytics solution, has over 500 registered early users across 15 countries despite no marketing or pricing efforts.
- Early feedback from users highlights significant efficiencies and potential life-saving capabilities, suggesting upside to product penetration beyond 2026 plans, which currently assume zero AI-related revenue.
Q3 2025
Nov 13, 2025
Cellebrite DI Ltd. reported robust third-quarter results for 2025, highlighted by strong growth in annual recurring revenue (ARR) and subscription sales, reflecting solid demand across key segments.
Key takeaways
- ARR grew by 19% year-over-year, with subscription revenue rising 21%, driven by strong performance in the U.S. state and local sectors.
- Adjusted EBITDA increased by 20%, accompanied by a 60 basis points margin expansion, underscoring efficiency improvements alongside revenue growth.
- The company successfully converted approximately 47% of its installed digital forensics license base to the insights offering, on target to surpass its 2025 goal.
- Cloud and SaaS solutions are gaining traction, with ARR for these offerings growing three times faster than total ARR, doubling the customer base for the Guardian solution year-over-year.
- Strategic investments in the defense and intelligence sector are proving fruitful, with increased adoption by global agencies for critical use cases.